New study tests if proton radiation can spare brain tissue without hurting survival
NCT ID NCT05190172
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares proton therapy to standard photon radiation for people with slow-growing brain tumors (IDH-mutated gliomas). The goal is to see if proton therapy, which targets tumors more precisely, can reduce side effects and maintain quality of life without shortening survival. About 225 adults aged 18-65 will take part, and researchers will track survival, fatigue, and thinking skills for two years after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (proton or photon)
What this could lead to
If proton therapy works as well as standard photon therapy, it could reduce side effects and improve quality of life for people with certain brain tumors.
What could go wrong
This is a mid-stage trial with 225 participants, so results are not final. Proton therapy might not be as effective at controlling the tumor, and long-term survival data are still being collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGODENDROGLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Oslo University Hospital
RECRUITINGOslo, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••